Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Thomas W. Flaig 1 , Maren Salzmann-Sullivan 1 , Lih-Jen Su 1 , Zhiyong Zhang 1 , Molishree Joshi 2 , Miguel A. Gijón 2 , Jihye Kim 1 , John J. Arcaroli 1 , Adrie Van Bokhoven 3 , M. Scott Lucia 3 , Francisco G. La Rosa 3 and Isabel R. Schlaepfer 1 1 Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA 2 Department of Pharmacology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA 3 Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA Correspondence to: Isabel R. Schlaepfer, email: // Keywords : CPT1A, prostate cancer, enzalutamide, ranolazine, INPP5K Received : February 27, 2017 Accepted : April 10, 2017 Published : April 21, 2017 Abstract Prostate cancer (PCa) is the most common malignancy among Western men and the second leading-cause of cancer related deaths. For men who develop metastatic castration resistant PCa (mCRPC), survival is limited, making the identification of novel therapies for mCRPC critical. We have found that deficient lipid oxidation via carnitine palmitoyltransferase (CPT1) results in decreased growth and invasion, underscoring the role of lipid oxidation to fuel PCa growth. Using immunohistochemistry we have found that the CPT1A isoform is abundant in PCa compared to benign tissue (n=39, p<0.001) especially in those with high-grade tumors. Since lipid oxidation is stimulated by androgens, we have evaluated the synergistic effects of combining CPT1A inhibition and anti-androgen therapy. Mechanistically, we have found that decreased CPT1A expression is associated with decreased AKT content and activation, likely driven by a breakdown of membrane phospholipids and activation of the INPP5K phosphatase. This results in increased androgen receptor (AR) action and increased sensitivity to the anti-androgen enzalutamide. To better understand the clinical implications of these findings, we have evaluated fat oxidation inhibitors (etomoxir, ranolazine and perhexiline) in combination with enzalutamide in PCa cell models. We have observed a robust growth inhibitory effect of the combinations, including in enzalutamide-resistant cells and mouse TRAMPC1 cells, a more neuroendocrine PCa model. Lastly, using a xenograft mouse model, we have observed decreased tumor growth with a systemic combination treatment of enzalutamide and ranolazine. In conclusion, our results show that improved anti-cancer efficacy can be achieved by co-targeting the AR axis and fat oxidation via CPT1A, which may have clinical implications, especially in the mCRPC setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“com/oncotarget Although new Highly-Effective Androgen Therapy (HEAT) such as the androgen receptor inhibitor Enzalutamide [6] and the androgen biosynthesis inhibitor Abiraterone acetate [7] have been shown to provide a survival advantage in mCRPC, virtually all patients acquire secondary resistance [8].”
BackgroundSelf-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · cited 3×
“Our results reinforce previous studies that AR-targeted therapy maybe insufficient to achieve long term PCa responses in some patients [8] and show that co-targeting the AR axis and fat oxidation may provide additional anti-cancer benefit.”
BackgroundResultThe androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624 · cited 1×
“com/oncotarget is known to stimulate aerobic glycolysis, lipid oxidation and several anabolic processes in PCa [13, 36, 37].”
BackgroundAkt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366
DeBerardinis, R. J., Lum, J. J., & Thompson, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608372200 · Cited by 221
Cited by
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Schlaepfer, I. R., & Joshi, M. (2020) · Endocrinology · doi:10.1210/endocr/bqz046 · Cited by 732
Self-citationLipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“Preclinical results further demonstrate significant tumor growth reduction with systemic combination treatment, suggesting that dual targeting of AR and lipid oxidation, including with perhexiline, may offer an effective strategy for mCRPC treatment [242].”
BackgroundLipid metabolism in cancer progression and therapeutic strategies
Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C., Zhao, Y., et al. (2021) · MedComm · doi:10.1002/mco2.27 · Cited by 393
Joshi, M., Kim, J., D’Alessandro, A., Monk, E., Bruce, K., Elajaili, H., Nozik-Grayck, E., Goodspeed, A., Costello, J. C., & Schlaepfer, I. R. (2020) · Cancers · doi:10.3390/cancers12113431 · Cited by 54
Self-citation
Metadata
- Authors
- Flaig, T. W., Salzmann-Sullivan, M., Su, L.-J., Zhang, Z., Joshi, M., Gijón, M. A., Kim, J., Arcaroli, J. J., Van Bokhoven, A., Lucia, M. S., La Rosa, F. G., & Schlaepfer, I. R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-04-21
- Volume
- 8
- Issue
- 34
- Pages
- 56051-56065
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2607413077
- Cited by
- 99
- References
- 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. https://app.cochat.ai/papers/10.18632/oncotarget.17359
- The paper
- Flaig, T. W., Salzmann-Sullivan, M., Su, L.-J., Zhang, Z., Joshi, M., Gijón, M. A., Kim, J., Arcaroli, J. J., Van Bokhoven, A., Lucia, M. S., La Rosa, F. G., & Schlaepfer, I. R. (2017). Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget. https://doi.org/10.18632/oncotarget.17359
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.